Angiogenesis in cutaneous disease: Part I

Journal of the American Academy of Dermatology

Volumn 61, Issue 6, 2009, Pages 921-942

  Nguyen, Amy ^a   Hoang, Van ^a   Laquer, Vivian ^b   Kelly, Kristen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California Irvine College of Medicine ^*  (United States)

Author keywords

angiogenesis; antiangiogenic agents; dermatology

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLEIOTROPHIN; PROGRANULIN; PROLIFERIN; PROTEIN KINASE B; RANIBIZUMAB; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANGIOSARCOMA; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM PERFORATION; DRUG FATALITY; DRUG MECHANISM; GENE EXPRESSION; HEMANGIOENDOTHELIOMA; HUMAN; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NEUROFIBROMA; NEVUS FLAMMEUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SCLERODERMA; SKIN BLOOD FLOW; SKIN CARCINOGENESIS; SKIN DISEASE; SKIN TUMOR; TUMOR VASCULARIZATION; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SKIN DISEASES;

EID: 71549114514     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.05.052     Document Type: Review

References (178)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 (2000) 389-395
4. Woessner Jr. J.F. That impish TIMP: the tissue inhibitor of metalloproteinases-3. J Clin Invest 108 (2001) 799-800
5. Raza S.L., and Cornelius L.A. Matrix metalloproteinases: pro- and anti-angiogenic activities. J Investig Dermatol Symp Proc 5 (2000) 47-54
6. Lafleur M.A., Handsley M.M., and Edwards D.R. Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 5 (2003) 1-39
7. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
8. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., and Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5 (1991) 1806-1814
9. Jakeman L.B., Winer J., Bennett G.L., Altar C.A., and Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89 (1992) 244-253
10. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
11. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., and Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269 (1994) 26988-26995
12. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735-745
13. Padera T.P., and Jain R.K. VEGFR3: a new target for antiangiogenesis therapy?. Dev Cell 15 (2008) 178-179
14. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
15. Curry J.M., Eubank T.D., Roberts R.D., Wang Y., Pore N., Maity A., et al. M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One 3 (2008) e3405
16. Nakatsu M.N., Sainson R.C., Perez-del-Pulgar S., Aoto J.N., Aitkenhead M., Taylor K.L., et al. VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest 83 (2003) 1873-1885
17. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 (1996) 1171-1180
18. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87 (1996) 1161-1169
19. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
20. Fiedler U., and Augustin H.G. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27 (2006) 552-558
21. Thurston G. Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 314 (2003) 61-68
22. Karamysheva A.F. Mechanisms of angiogenesis. Biochemistry (Mosc) 73 (2008) 751-762
23. Holash J., Wiegand S.J., and Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18 (1999) 5356-5362
24. Arese M., Chen Y., Florkiewicz R.Z., Gualandris A., Shen B., and Rifkin D.B. Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol Biol Cell 10 (1999) 1429-1444
25. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 (2002) 795-803
26. Arbiser J.L., Byers H.R., Cohen C., and Arbeit J. Altered basic fibroblast growth factor expression in common epidermal neoplasms: examination with in situ hybridization and immunohistochemistry. J Am Acad Dermatol 42 (2000) 973-977
27. Gospodarowicz D. Fibroblast growth factor. Chemical structure and biologic function. Clin Orthop Relat Res 257 (1990) 231-248
28. O'Keefe E.J., and Chiu M.L. Stimulation of thymidine incorporation in keratinocytes by insulin, epidermal growth factor, and placental extract: comparison with cell number to assess growth. J Invest Dermatol 90 (1988) 2-7
29. Hebda P.A., Klingbeil C.K., Abraham J.A., and Fiddes J.C. Basic fibroblast growth factor stimulation of epidermal wound healing in pigs. J Invest Dermatol 95 (1990) 626-631
30. Greenhalgh D.G., Sprugel K.H., Murray M.J., and Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 136 (1990) 1235-1246
31. Fauci A.S. Harrison's principles of internal medicine. In: Fauci A.S., Braunwald E., Kasper D.L., hauser S.L., Longo D.L., Jameson L., et al. (Eds) (2008), McGraw-Hill Companies, New York
32. Halaban R., Kwon B.S., Ghosh S., Delli Bovi P., and Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 3 (1988) 177-186
33. Becker D., Meier C.B., and Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 8 (1989) 3685-3691
34. Waugh D.J., and Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 14 (2008) 6735-6741
35. Brat D.J., Bellail A.C., and Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7 (2005) 122-133
36. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161 (2002) 125-134
37. In: Davis D.W., Herbst R.S., and Abbruzzese J.L. (Eds). Antiangiogenic cancer therapy (2007), CRC Press Taylor & Francis Group, Boca Raton (FL)
38. Fredriksson L., Li H., and Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15 (2004) 197-204
39. Andrae J., Gallini R., and Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22 (2008) 1276-1312
40. Heldin C.H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79 (1999) 1283-1316
41. Cheng B., Liu H., Fu X., Sheng Z., and Sun T. Recombinant human platelet-derived growth factor enhances repair of cutaneous full-thickness excision by increasing the phosphorylation of extracellular signal-regulated kinase in diabetic rat. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20 (2006) 1093-1098
42. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15 (2004) 255-273
43. Klareskog L., Gustafsson R., Scheynius A., and Hallgren R. Increased expression of platelet derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33 (1990) 1534-1541
44. Werner S., Hofschneider P.H., Heldin C.H., Ostman A., and Roth W.K. Cultured Kaposi's sarcoma-derived cells express functional PDGF A-type and B-type receptors. Exp Cell Res 187 (1990) 98-103
45. Javelaud D., Alexaki V.I., and Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 21 (2008) 123-132
46. Bandyopadhyay A., Agyin J.K., Wang L., Tang Y., Lei X., Story B.M., et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 66 (2006) 6714-6721
47. Kesari A.L., Chellam V.G., Mathew B.S., Nair M.K., and Pillai M.R. Transforming growth factor beta related to extent of tumor angiogenesis but not apoptosis or proliferation in breast carcinoma. Breast Cancer 6 (1999) 29-36
48. Wang X., and Lin Y. Tumor necrosis factor and cancer, buddies or foes?. Acta Pharmacol Sin 29 (2008) 1275-1288
49. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10 (2003) 45-65
50. Yang J., Lin Y., Guo Z., Cheng J., Huang J., Deng L., et al. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol 2 (2001) 620-624
51. Devin A., Lin Y., and Liu Z.G. The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep 4 (2003) 623-627
52. Frater-Schroder M., Risau W., Hallmann R., Gautschi P., and Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A 84 (1987) 5277-5281
53. Leibovich S.J., Polverini P.J., Shepard H.M., Wiseman D.M., Shively V., and Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329 (1987) 630-632
54. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
55. Claesson-Welsh L., Welsh M., Ito N., Anand-Apte B., Soker S., Zetter B., et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 95 (1998) 5579-5583
56. Dass C.R., Tran T.M., and Choong P.F. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. J Dent Res 86 (2007) 927-936
57. Kurup A., Lin C.W., Murry D.J., Dobrolecki L., Estes D., Yiannoutsos C.T., et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 17 (2006) 97-103
58. Beerepoot L.V., Witteveen E.O., Groenewegen G., Fogler W.E., Sim B.K., Sidor C., et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res 9 (2003) 4025-4033
59. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
60. Kim Y.M., Hwang S., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277 (2002) 27872-27879
61. Dixelius J., Cross M., Matsumoto T., Sasaki T., Timpl R., and Claesson-Welsh L. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 62 (2002) 1944-1947
62. Taddei L., Chiarugi P., Brogelli L., Cirri P., Magnelli L., Raugei G., et al. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun 263 (1999) 340-345
63. Nyberg P., Heikkila P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U.H., et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 278 (2003) 22404-22411
64. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 98 (2001) 1024-1029
65. Indraccolo S., Gola E., Rosato A., Minuzzo S., Habeler W., Tisato V., et al. Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther 9 (2002) 867-878
66. Wang L., Wu W.Z., Sun H.C., Wu X.F., Qin L.X., Liu Y.K., et al. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 7 (2003) 587-594
67. Raig E.T., Jones N.B., Varker K.A., Benniger K., Go M.R., Biber J.L., et al. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res 28 (2008) 553-561
68. McCarty M.F., Bielenberg D., Donawho C., Bucana C.D., and Fidler I.J. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 19 (2002) 609-615
69. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 13 (2007) 4677-4685
70. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., and Lejeune F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4 (1998) 408-414
71. Dias S., Boyd R., and Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 78 (1998) 361-365
72. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., and Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87 (1995) 581-586
73. Coughlin C.M., Salhany K.E., Gee M.S., LaTemple D.C., Kotenko S., Ma X., et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9 (1998) 25-34
74. Kazerounian S., Yee K.O., and Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 65 (2008) 700-712
75. Silverstein R.L., and Febbraio M. CD36-TSP-HRGP interactions in the regulation of angiogenesis. Curr Pharm Des 13 (2007) 3559-3567
76. Greenaway J., Lawler J., Moorehead R., Bornstein P., Lamarre J., and Petrik J. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210 (2007) 807-818
77. Volpert O.V., Tolsma S.S., Pellerin S., Feige J.J., Chen H., Mosher D.F., et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 217 (1995) 326-332
78. Fontana A., Filleur S., Guglielmi J., Frappart L., Bruno-Bossio G., Boissier S., et al. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer 116 (2005) 686-691
79. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
80. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477 (2000) 267-283
81. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
82. Khwaja A. Akt is more than just a Bad kinase. Nature 401 (1999) 33-34
83. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 13 (1999) 2905-2927
84. Fujio Y., and Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274 (1999) 16349-16354
85. Kim I., Kim H.G., So J.N., Kim J.H., Kwak H.J., and Koh G.Y. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 86 (2000) 24-29
86. Dimmeler S., Assmus B., Hermann C., Haendeler J., and Zeiher A.M. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res 83 (1998) 334-341
87. Hermann C., Assmus B., Urbich C., Zeiher A.M., and Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 20 (2000) 402-409
88. Shiojima I., and Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90 (2002) 1243-1250
89. Igarashi J., Bernier S.G., and Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. Differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem 276 (2001) 12420-12426
90. Panetti T.S., Nowlen J., and Mosher D.F. Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration. Arterioscler Thromb Vasc Biol 20 (2000) 1013-1019
91. Dormond O., Madsen J.C., and Briscoe D.M. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 282 (2007) 23679-23686
92. Thomas G.V. mTOR and cancer: reason for dancing at the crossroads?. Curr Opin Genet Dev 16 (2006) 78-84
93. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 (2004) 1926-1945
94. Kwiatkowski D.J. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol Ther 2 (2003) 471-476
95. Inoki K., Li Y., Xu T., and Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17 (2003) 1829-1834
96. Manning B.D., and Cantley L.C. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 28 (2003) 573-576
97. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002) 177-189
98. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163-175
99. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
100. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399 (1999) 597-601
101. Papapetropoulos A., Garcia-Cardena G., Madri J.A., and Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100 (1997) 3131-3139
102. Murohara T., Asahara T., Silver M., Bauters C., Masuda H., Kalka C., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101 (1998) 2567-2578
103. Murohara T., Witzenbichler B., Spyridopoulos I., Asahara T., Ding B., Sullivan A., et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 19 (1999) 1156-1161
104. Noiri E., Lee E., Testa J., Quigley J., Colflesh D., Keese C.R., et al. Podokinesis in endothelial cell migration: role of nitric oxide. Am J Physiol 274 (1998) C236-C244
105. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 (2004) 1296-1302
106. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22 (2006) 159-168
107. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
108. Holmgren L. Antiangiogenis restricted tumor dormancy. Cancer Metastasis Rev 15 (1996) 241-245
109. Hirota K., and Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59 (2006) 15-26
110. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
111. Yamakawa M., Liu L.X., Date T., Belanger A.J., Vincent K.A., Akita G.Y., et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 93 (2003) 664-673
112. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7004-7014
113. Pore N., Jiang Z., Shu H.K., Bernhard E., Kao G.D., and Maity A. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4 (2006) 471-479
114. Peyssonnaux C., Datta V., Cramer T., Doedens A., Theodorakis E.A., Gallo R.L., et al. HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest 115 (2005) 1806-1815
115. Peyssonnaux C., Boutin A.T., Zinkernagel A.S., Datta V., Nizet V., and Johnson R.S. Critical role of HIF-1alpha in keratinocyte defense against bacterial infection. J Invest Dermatol 128 (2008) 1964-1968
116. Li Y., Bi Z., Yan B., and Wan Y. UVB radiation induces expression of HIF-1alpha and VEGF through the EGFR/PI3 K/DEC1 pathway. Int J Mol Med 18 (2006) 713-719
117. Million R.P. Therapeutic area crossroads: anti-angiogenesis. Nature Reviews Drug Discovery 7 (2008) 115-116
118. Ferrara N., Houck K.A., Jakeman L.B., Winer J., and Leung D.W. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47 (1991) 211-218
119. Spitzer M.S., Yoeruek E., Sierra A., Wallenfels-Thilo B., Schraermeyer U., Spitzer B., et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 245 (2007) 1837-1842
120. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5 (2007) 203-220
121. Vincenzi B., Santini D., Russo A., Silletta M., Gavasci M., Battistoni F., et al. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol 17 (2006) 835-841
122. Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5 (1999) 257-265
123. Luwor R.B., Lu Y., Li X., Mendelsohn J., and Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24 (2005) 4433-4441
124. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
125. Huang S.M., Li J., and Harari P.M. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 1 (2002) 507-514
126. Fracasso P.M., Burris III H., Arquette M.A., Govindan R., Gao F., Wright L.P., et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13 (2007) 986-993
127. Harding J., and Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 41 (2005) 107-127
128. Bernier J. Drug insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Nat Clin Pract Oncol 5 (2008) 705-713
129. Cohenuram M., and Saif M.W. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18 (2007) 7-15
130. Carteni G., Fiorentino R., Vecchione L., Chiurazzi B., and Battista C. Panitumumab a novel drug in cancer treatment. Ann Oncol 18 suppl 6 (2007) vi16-vi21
131. Nahta R., and Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 26 (2007) 3637-3643
132. Izumi Y., Xu L., di Tomaso E., Fukumura D., and Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416 (2002) 279-280
133. Nguyen S., Franklin M., and Dudek A.Z. Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib. Transl Res 151 (2008) 194-196
134. Perdona S., Di Trolio R., Di Lorenzo G., and Autorino R. A case of renal melanoma metastasis: description of clinico-pathological features. Arch Ital Urol Androl 79 (2007) 161-163
135. Ng R., and Chen E.X. Sorafenib (BAY 43-9006): review of clinical development. Curr Clin Pharmacol 1 (2006) 223-228
136. Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I., Links T.P., et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282 (2007) 29230-29240
137. Pore N., Jiang Z., Gupta A., Cerniglia G., Kao G.D., and Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66 (2006) 3197-3204
138. Brown P.D., and Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6 (1995) 967-974
139. Hoekstra R., Eskens F.A., and Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 6 (2001) 415-427
140. Sauder D.N., Dekoven J., Champagne P., Croteau D., and Dupont E. Neovastat (AE-941), an inhibitor of angiogenesis: randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 47 (2002) 535-541
141. Gutierrez-Dalmau A., Sanchez-Fructuoso A., Sanz-Guajardo A., Mazuecos A., Franco A., Rial M.C., et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 37 (2005) 3836-3838
142. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
143. Guenova E., Metzler G., Hoetzenecker W., Berneburg M., and Rocken M. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 144 (2008) 692-693
144. Schaffer M., Schier R., Napirei M., Michalski S., Traska T., and Viebahn R. Sirolimus impairs wound healing. Langenbecks Arch Surg 392 (2007) 297-303
145. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Gostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
146. Chumsri S., Zhao M., Garofalo M., Burger A., Hamburger A., Zhao F., et al. Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Leuk Lymphoma 49 (2008) 359-361
147. Zhang Q., Nowak I., Vonderheid E.C., Rook A.H., Kadin M.E., Nowell P.C., et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sézary syndrome. Proc Natl Acad Sci U S A 93 (1996) 9148-9153
148. Saggar S., Zeichner J.A., Brown T.T., Phelps R.G., and Cohen S.R. Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris. Arch Dermatol 144 (2008) 654-657
149. Hofbauer G.F., Marcollo-Pini A., Corsenca A., Kistler A.D., French L.E., Wuthrich R.P., et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 159 (2008) 473-475
150. Reitamo S., Spuls P., Sassolas B., Lahfa M., Claudy A., and Griffiths C.E. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145 (2001) 438-445
151. Zeng Z., Sarbassov dos D., Samudio I.J., Yee K.W., Munsell M.F., Ellen Jackson C., et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109 (2007) 3509-3512
152. Bianco R., Garofalo S., Rosa R., Damiano V., Gelardi T., Daniele G., et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98 (2008) 923-930
153. Cejka D., Preusser M., Woehrer A., Sieghart W., Strommer S., Werzowa J., et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 7 (2008) 1377-1385
154. Frigerio E., Colombo M.D., Franchi C., Altomare A., Garutti C., and Altomare G.F. Severe psoriasis treated with a new macrolide: everolimus. Br J Dermatol 156 (2007) 372-374
155. Roccaro A.M., Hideshima T., Raje N., Kumar S., Ishitsuka K., Yasui H., et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66 (2006) 184-191
156. Zinzani P.L., Musuraca G., Tani M., Stefoni V., Marchi E., Fina M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007) 4293-4297
157. Miller R.L., Gerster J.F., Owens M.L., Slade H.B., and Tomai M.A. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 21 (1999) 1-14
158. Suzuki H., Wang B., Shivji G.M., Toto P., Amerio P., Tomai M.A., et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 114 (2000) 135-141
159. Testerman T.L., Gerster J.F., Imbertson L.M., Reiter M.J., Miller R.L., Gibson S.J., et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 58 (1995) 365-372
160. Majewski S., Marczak M., Mlynarczyk B., Benninghoff B., and Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 44 (2005) 14-19
161. Hesling C., D'Incan M., Mansard S., Franck F., Corbin-Duval A., Chevenet C., et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 150 (2004) 761-767
162. Li V.W., Li W.W., Talcott K.E., and Zhai A.W. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 4 (2005) 708-717
163. Gul U., Gonul M., Cakmak S.K., Kilic A., and Demiriz M. A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. Adv Ther 23 (2006) 787-792
164. Chang C.J., Hsiao Y.C., Mihm Jr. M.C., and Nelson J.S. Pilot study examining the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks. Lasers Surg Med 40 (2008) 605-610
165. Tremaine AM, Ortiz A, Armstrong J, Huang Y-C, Elkeeb L, Choi B, Kelly KM. Combined therapy for enhanced microvascular destruction in port wine stains: pulsed dye laser photothermolysis and imiquimod. Presented at: Annual Meeting of the American Society for Laser Medicine and Surgery; 2009; Washington DC.
166. Li X., Liu X., Wang J., Wang Z., Jiang W., Reed E., et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 23 (2003) 2481-2487
167. Rosenbach M., and Werth V.P. Dermatologic therapeutics: thalidomide. A practical guide. Dermatol Ther 20 (2007) 175-186
168. Wilson C., Scullin P., Worthington J., Seaton A., Maxwell P., O'Rourke D., et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br J Cancer 99 (2008) 2054-2064
169. Sung J., Barone P.W., Kong H., and Strano M.S. Sequential delivery of dexamethasone and VEGF to control local tissue response for carbon nanotube fluorescence based micro-capillary implantable sensors. Biomaterials 30 (2009) 622-631
170. El Filali M., Homminga I., Maat W., van der Velden P.A., and Jager M.J. Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. Mol Vis 14 (2008) 1752-1759
171. Michaud A.P., Bauman N.M., Burke D.K., Manaligod J.M., and Smith R.J. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 114 (2004) 1231-1236
172. Ezekowitz R.A., Mulliken J.B., and Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326 (1992) 1456-1463
173. Brandling-Bennett H.A., Metry D.W., Baselga E., Lucky A.W., Adams D.M., Cordisco M.R., et al. Infantile hemangiomas with unusually prolonged growth phase: a case series. Arch Dermatol 144 (2008) 1632-1637
174. Hoekstra R., de Vos F.Y., Eskens F.A., Gietema J.A., van der Gaast A., Groen H.J., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 23 (2005) 5188-5197
175. Markovic S.N., Suman V.J., Rao R.A., Ingle J.N., Kaur J.S., Erickson L.A., et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30 (2007) 303-309
176. Smiell J.M., Wieman T.J., Steed D.L., Perry B.H., Sampson A.R., and Schwab B.H. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 7 (1999) 335-346
177. Cohen M.A., and Eaglstein W.H. Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds. J Am Acad Dermatol 45 (2001) 857-862
178. Metz B.J., Rubenstein M.C., Levy M.L., and Metry D.W. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 140 (2004) 867-870